-
Mashup Score: 85The Standard (S4, E8): Draft Ready | Pittsburgh Steelers - 11 day(s) ago
This episode features exclusive access with Omar Khan and Coach Tomlin at Pro Days, Pittsburgh native and scout Jim Ward, and a Kicking Clinic in Ireland#Her…
Source: www.youtube.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 88Eli Lilly's Zepbound eases obstructive sleep apnea in trials - 17 day(s) ago
Eli Lilly reported Wednesday that the GLP-1 drug cut breathing interruptions in obese or overweight patients experiencing the condition.
Source: www.statnews.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 88Eli Lilly's Zepbound eases obstructive sleep apnea in trials - 17 day(s) ago
Eli Lilly reported Wednesday that the GLP-1 drug cut breathing interruptions in obese or overweight patients experiencing the condition.
Source: www.statnews.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 87Eli Lilly's Zepbound eases obstructive sleep apnea in trials - 18 day(s) ago
Eli Lilly reported Wednesday that the GLP-1 drug cut breathing interruptions in obese or overweight patients experiencing the condition.
Source: www.statnews.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 87Eli Lilly's Zepbound eases obstructive sleep apnea in trials - 18 day(s) ago
Eli Lilly reported Wednesday that the GLP-1 drug cut breathing interruptions in obese or overweight patients experiencing the condition.
Source: www.statnews.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 254Obesity treatment from Boehringer Ingelheim, Zealand Pharma succeeds in study in liver condition MASH - 2 month(s) ago
A drug in development as a weight loss treatment succeeded in a Phase 2 study in a serious liver condition, as the competition in the obesity medicine field pushes ahead.
Source: www.statnews.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 247Obesity treatment from Boehringer Ingelheim, Zealand Pharma succeeds in study in liver condition MASH - 2 month(s) ago
A drug in development as a weight loss treatment succeeded in a Phase 2 study in a serious liver condition, as the competition in the obesity medicine field pushes ahead.
Source: www.statnews.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 68
The drug industry officially has two new heavyweights. For the first time, Regeneron and Vertex have crossed the $100 billion market cap threshold. They join about 15 other drugmakers that count as the industry’s biggest, and include other giants like Johnson & Johnson, Merck, and Novartis. And while it’s an
Source: endpts.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 41'The Top Line': Gene editing's next act - 3 month(s) ago
Gene editing’s therapeutic application has transitioned from hypothetical to reality, marked by the recent approval of a CRISPR-based therapy for sickle cell and beta thalassemia. | This week on “The Top Line,” Max Bayer from Fierce Biotech explores the future of gene editing in an interview with the CEO of Verve Therapeutics.
Source: www.fiercepharma.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 8
Newly named partner Anthony Philippakis and managing partner Krishna Yeshwant spoke with BioPharma Dive about biotech’s newfound optimism and their investing “North Star.”
Source: www.biopharmadive.comCategories: General Medicine News, CardiologistsTweet
RT @steelers: Draft ready ⏰ Check out the newest episode of The Standard ➡️ https://t.co/OX9MEkAKMc https://t.co/yMRsdCl1Ot